L. Mucke et al., PROTECTION AGAINST HIV-1 GP120-INDUCED BRAIN-DAMAGE BY NEURONAL EXPRESSION OF HUMAN AMYLOID PRECURSOR PROTEIN, The Journal of experimental medicine, 181(4), 1995, pp. 1551-1556
Expression of the HIV-1 envelope protein gp120 in brains of transgenic
(tg) mice induces extensive neurodegeneration (Toggas, S. M., E. Masl
iah, E. M. Rockenstein, G. F. Rall, C. R. Abraham, and L. Mucke. 1994.
Nature [Lend.]. 367:188-193.). To further analyze the pathogenesis of
gp120-induced neurotoxicity and to assess the neuroprotective potenti
al of human amyloid precursor proteins (hAPPs) in vivo, different hAPP
isoforms were expressed in neurons of gp120/hAPP-bigenic mice: hAPP75
1, which contains a Kunitz-type protease inhibitor domain, or hAPP695,
which lacks this domain. Bigenic mice overexpressing hAPP751 at moder
ate levels showed significantly less neuronal loss, synapto-dendritic
degeneration, and gliosis than singly tg mice expressing gp120 alone.
In contrast, higher levels of hAPP695 expression in bigenic mice faile
d to prevent gp120-induced brain damage. These data indicate that hAPP
can exert important neuroprotective functions in vivo and that the ef
ficiency of this protection may depend on the hAPP isoform expressed a
nd/or on the level of neuronal hAPP expression. Hence, molecules that
mimic beneficial APP activities may be useful in the prevention/treatm
ent of HIV-1-associated nervous system damage and, perhaps, also of ot
her types of neural injury.